More recently, two specific inhibitors of cytochrome c release lacking additional multifunctional activity—methazolamide (MTZ) and melatonin (MEL)—were identified by screening a library of compounds (NINDS Drug Screening Consortium) on isolated mitochondria [22] and proved to be neuroprotective in models of Huntington’s disease and ischemic injury [22, 23]. Here, CYCS is linked to juvenile Huntington disease.